Previous 10 | Next 10 |
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announce...
AXIM Biotechnologies (AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19.Measuring neutralizing antibodies in people after vaccination may give a better...
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced...
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 r...
AXIM Biotechnologies ([[AXIM]] -2.4%) has filed an amended Emergency Use Authorization ((EUA)) application with the FDA.AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The Company amended the EUA to in...
SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced...
SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced...
SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, annou...
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 resea...
AXIM Biotechnologies ([[AXIM]]) has filed a provisional patent for a recombinant virus binding protein ((VBP)) for SARS-CoV-2, and is now manufacturing the VBP.According number of studies, SARS-CoV-2’s spike protein enters human host cells by locking its receptor binding...
News, Short Squeeze, Breakout and More Instantly...
Axim Biotechnologies Inc Company Name:
AXIM Stock Symbol:
OTCMKTS Market:
Axim Biotechnologies Inc Website:
State of California Department of Public Heath Food and Drug Branch Issues the Company a License for Manufacturing of its Diagnostic Assays SAN DIEGO, CA - ( NewMediaWire ) - May 29, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” ...
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA - ( NewMediaWire ) - March 27, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,...
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA - ( NewMediaWire ) - February 20, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” ...